Mark Yan

420 total citations
8 papers, 148 citations indexed

About

Mark Yan is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Mark Yan has authored 8 papers receiving a total of 148 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Mark Yan's work include Acute Myeloid Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mark Yan is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mark Yan collaborates with scholars based in Canada, United States and Switzerland. Mark Yan's co-authors include Elicia Penuel, Franck Morschhauser, Dan Lü, Jeff P. Sharman, Hervé Tilly, Corinne Haïoun, Nancy L. Bartlett, Amitkumar Mehta, Javier Muñoz and Kathryn S. Kolibaba and has published in prestigious journals such as Blood, The Lancet Oncology and Leukemia.

In The Last Decade

Mark Yan

8 papers receiving 145 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Yan Canada 4 96 60 44 34 29 8 148
Catalina Amador United States 7 46 0.5× 64 1.1× 27 0.6× 39 1.1× 40 1.4× 19 132
Julia González‐Rincón Spain 5 53 0.6× 73 1.2× 9 0.2× 19 0.6× 28 1.0× 7 106
Cassandra Choe-Juliak United States 5 124 1.3× 69 1.1× 8 0.2× 21 0.6× 80 2.8× 7 151
Barbara Mantoan Italy 7 71 0.7× 106 1.8× 36 0.8× 28 0.8× 11 0.4× 13 155
Stefan Köhrer Austria 4 42 0.4× 54 0.9× 32 0.7× 69 2.0× 30 1.0× 11 153
Maneesh Tandon United Kingdom 8 65 0.7× 99 1.6× 16 0.4× 9 0.3× 35 1.2× 18 138
Austin I. Kim United States 7 55 0.6× 129 2.1× 42 1.0× 14 0.4× 50 1.7× 17 179
Esther Hian Li Chan Singapore 6 66 0.7× 43 0.7× 7 0.2× 27 0.8× 28 1.0× 17 106
Susana Ben Neriah Canada 4 80 0.8× 134 2.2× 12 0.3× 18 0.5× 29 1.0× 5 158
Sven Turkalj United Kingdom 5 31 0.3× 31 0.5× 34 0.8× 47 1.4× 39 1.3× 9 114

Countries citing papers authored by Mark Yan

Since Specialization
Citations

This map shows the geographic impact of Mark Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Yan more than expected).

Fields of papers citing papers by Mark Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Yan. The network helps show where Mark Yan may publish in the future.

Co-authorship network of co-authors of Mark Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Yan. A scholar is included among the top collaborators of Mark Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Yan. Mark Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
2.
Prébet, Thomas, Aaron D. Goldberg, Joseph G. Jurcic, et al.. (2022). A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia & lymphoma. 63(9). 2180–2188. 6 indexed citations
3.
Gerds, Aaron T., Bart L. Scott, Peter L. Greenberg, et al.. (2021). Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances. 6(4). 1152–1161. 19 indexed citations
4.
Yan, Mark, Yi Meng Chang, Vibha Raghavan, et al.. (2020). Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 29–30. 2 indexed citations
5.
Tilly, Hervé, Franck Morschhauser, Nancy L. Bartlett, et al.. (2019). Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. The Lancet Oncology. 20(7). 998–1010. 93 indexed citations
6.
7.
Gerds, Aaron T., Bart L. Scott, Peter L. Greenberg, et al.. (2018). PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. Blood. 132(Supplement 1). 466–466. 24 indexed citations
8.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catalina Amador Breakdown of academic impact, for papers by Julia González‐Rincón Breakdown of academic impact, for papers by Cassandra Choe-Juliak Breakdown of academic impact, for papers by Barbara Mantoan Breakdown of academic impact, for papers by Stefan Köhrer Breakdown of academic impact, for papers by Maneesh Tandon Breakdown of academic impact, for papers by Austin I. Kim Breakdown of academic impact, for papers by Esther Hian Li Chan Breakdown of academic impact, for papers by Susana Ben Neriah Breakdown of academic impact, for papers by Sven Turkalj
Rankless by CCL
2026